• Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
Stock

L’Oréal buys Medik8, expanding its portfolio in anti-aging skincare market

by June 9, 2025
by June 9, 2025

French cosmetics behemoth L’Oréal is set to acquire Medik8, a British skincare brand renowned for its vitamin A-based anti-aging products.

The deal, announced Monday by Medik8’s current owner, UK-based private equity firm Inflexion, marks another strategic move by L’Oréal to deepen its presence in the rapidly expanding and highly lucrative dermatological skincare market.

While the financial terms of the acquisition were not disclosed, the addition of Medik8 is poised to enhance L’Oréal’s already formidable dermatological beauty division.

This unit, which boasts powerhouse brands such as CeraVe, La Roche-Posay, and SkinCeuticals, has been L’Oréal’s fastest-growing segment in recent years.

It achieved impressive revenues of 7 billion euros ($7.99 billion) last year, following nearly 10% growth from the year prior.

This division is also notable for having the highest profit margin among L’Oréal’s four main business units.

The surge in consumer interest for science-backed skincare products has been a primary driver of this division’s success.

However, growth in this popular category has recently shown signs of moderation due to intensifying competition from both established players and emerging niche brands.

Strategic acquisition drive: reviving growth and expanding reach

L’Oréal executives have openly stated this year that the company is actively pursuing acquisitions as a strategy to revive flagging growth in certain areas and to further expand its global footprint.

The Medik8 purchase aligns perfectly with this objective.

This latest acquisition follows L’Oréal’s move in December to buy Korean skincare brand Dr.G and its acquisition of a minority stake in Oman-based luxury perfume house Amouage last year, signaling a consistent appetite for strategic additions to its portfolio.

Inflexion, the private equity firm selling Medik8, will retain a minority shareholding in the brand as part of the transaction.

According to a statement from Inflexion, “The partnership with L’Oreal will allow Medik8 to deepen its presence in existing markets and expand globally.”

This suggests a collaborative approach to nurturing Medik8’s future growth under L’Oréal’s ownership, leveraging the French giant’s extensive global distribution network and marketing prowess.

The post L’Oréal buys Medik8, expanding its portfolio in anti-aging skincare market appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Is full self-driving real or just hype? Promise, progress, and what’s on the road
next post
Europe markets open: stocks dip ahead of key US-China meeting; Chinese trade data disappoints

Related Posts

Hang Seng Index steady ahead of Alibaba, Tencent,...

March 17, 2026

Why Bright Smart stock surged over 82% on...

March 17, 2026

Bitcoin climbs as ETF inflows hit multi-day streak,...

March 17, 2026

Samsung stock rises: can Nvidia revive its struggling...

March 17, 2026

Tesla, LG lock $4.3B battery deal: here’s what...

March 17, 2026

Rolls-Royce share price sinks amid the US-Iran war:...

March 17, 2026

EV race heats up as BYD lands 100K...

March 17, 2026

IDBI stock tanks 15%: buy the dip or...

March 16, 2026

Brokerages cut Nifty targets as Middle East war...

March 16, 2026

Foxconn earnings miss despite record AI demand: what...

March 16, 2026

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

Recent Posts

  • Gemini stock: Will Winklevoss Twins’ company crash below $5 after earnings?

    March 18, 2026
  • Europe bulletin: stocks rise, Bentley cuts jobs, Audi sees rebound

    March 18, 2026
  • Swarmer stock soars 700% in blockbuster AI drone IPO debut

    March 18, 2026
  • Dow Jones rises as oil above $103, Fed meeting in focus

    March 18, 2026
  • Asian markets climb as oil dips, Fed decision keeps traders cautious

    March 18, 2026
  • Microsoft vs Amazon on OpenAI deal: what’s really at stake here?

    March 18, 2026

Editors’ Picks

  • 1

    Pop Mart reports 188% profit surge, plans aggressive global expansion

    March 26, 2025
  • 2

    New FBI leader Kash Patel tapped to run ATF as acting director

    February 23, 2025
  • 3

    Meta executives eligible for 200% salary bonus under new pay structure

    February 21, 2025
  • 4

    Anthropic’s newly released Claude 3.7 Sonnet can ‘think’ as long as the user wants before giving an answer

    February 25, 2025
  • 5

    Walmart earnings preview: What to expect before Thursday’s opening bell

    February 20, 2025
  • ‘The Value of Others’ Isn’t Especially Valuable

    April 17, 2025
  • 7

    Cramer reveals a sub-sector of technology that can withstand Trump tariffs

    March 1, 2025

Categories

  • Economy (4,448)
  • Editor's Pick (558)
  • Investing (784)
  • Stock (2,813)
  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Read alsox

Panama Canal ports deal faces uncertainty as...

July 28, 2025

DocuSign stock price forecast: could explode higher...

March 11, 2025

China to relax rare earth export rules...

November 7, 2025